Navigation Links
Global Melanoma Therapeutics Industry
Date:6/28/2010

NEW YORK, June 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Melanoma Therapeutics industry

http://www.reportlinker.com/p0197206/Global-Melanoma-Therapeutics-industry.html

This report analyzes the worldwide markets for Melanoma Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 73 companies including many key and niche players such as Abraxis BioScience, Inc., Astellas Pharma US, Inc., Antigenics Inc., AVAX Technologies, Inc., BioVex, Inc., GenVec, Inc., GlaxoSmithKline Plc., Medarex Inc., Merck KGAA, Oxford Biomedica Plc, Pfizer, Inc., Progen Pharmaceuticals Limited, and Vical Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

MELANOMA THERAPEUTICS MCP-6303

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1

Melanoma Incidence Surging at Significant Rate II-1

Current Standard Treatment for Melanoma II-1

High Unmet Need, and Challenges Abound II-1

Recommencement of Discontinued Trials Provides a Ray a Hope! II-2

Cancer Vaccines: Potentially a Future Aid for Melanoma Treatment II-2

How Does Cancer Vaccines Works? II-3

Whole Cell Vaccines for Melanoma II-3

Melanoma Therapeutics Market: Current & Future Analysis II-3

2. MELANOMA PIPELINE - AN OVERVIEW II-4

Research for Novel Drug Therapies Rampant Worldwide II-4

Selected Products and Targets for Melanoma Treatment Under

Phase III Clinical Trials (As of 2008) II-4

Selected Products and Targets for Melanoma Treatment Under

Phase II Clinical Trials (As of 2008) II-5

Selected Products and Targets for Melanoma Treatment Under

Phase I and Pre-Clinical Trials (As of 2008) II-7

Major Drugs Under Investigations for Metastatic Melanoma

Treatment (As of 2008) II-8

What Does the Future Hold for Melanoma in Vaccines Space? II-8

Pipeline Analysis of Melanoma Vaccines II-8

Select Companies with Melanoma Vaccines under Phase III

Clinical Trials II-8

Select Companies with Melanoma Vaccines under Phase II

Clinical Trials II-9

Select Companies with Melanoma Vaccines under Phase I

Clinical Trials II-9

3. MELANOMA: THE DISEASE AND TREATMENT II-10

What is Melanoma? II-10

Melanoma of Skin: A Grave form of Skin Cancer II-10

Melanoma Vis-à-vis Other Skin Cancers II-10

Types of Melanoma II-11

Risk Factors for Melanoma II-11

Indoor Tanning Devices Hold Potential for Causing Skin Cancer II-11

Fair Skinned People: At Greater Risk II-12

Prevention of Melanoma II-12

How Is Melanoma Detected? II-12

Ugly Duckling Sign - A New Approach for Melanoma Detection II-12

Diagnosis of Melanoma II-13

Skin Biopsy, an Initial Step II-13

Fine Needle Aspirate (FNA) II-13

Shave Biopsy II-13

Punch Biopsy II-13

Incisional Biopsy II-13

Excisional Biopsy II-13

Process After Biopsy: A Review II-13

Analysis of Lymph Nodes Status, A Second Step II-14

Lactate Dehydrogenase Tests for Metastases Melanoma II-14

Prognosis of the Disease II-14

Melanoma Staging: Crucial for Treatment II-15

Melanoma Treatment: An Overview II-15

Surgical Excision of Melanoma II-16

Sentinel Lymph Node Biopsy II-16

Standard Treatment, Post Surgery II-16

Surgical Adjuvant Treatment II-17

Standard Excision for Lentigo Maligna II-17

Surgical Treatment of Metastatic Melanoma II-17

Stereotactic Radiosurgery For Brain Metastases Melanoma II-18

Chemotherapy for Melanoma II-18

Side Effects II-18

Chemotherapeutic Regional Perfusion II-19

Immunotherapy for Melanoma II-19

Biochemotherapy: Chemo Plus Biotherapy II-19

Radiation Therapy II-20

Vaccine Immunotherapy II-20

Other Treatments II-20

4. RESEARCH FINDINGS II-21

Vitamin D May Prevent Severe Melanoma Lesions II-21

Stress Accelerates Growth Of Melanoma Lesions II-21

Interaction Between Akt3 and (V600E)B-Raf Proteins in a Mole,

Leads to Melanoma II-21

5. RESEARCH & DEVELOPMENT II-22

Synta Obtains FDA Approval to Resume Development of Elesclomol II-22

Nexavar Fails in Late Stage Melanoma Trial II-22

Biovex Commences Phase III Clinical Trial of Oncovexgm-CSF II-22

Medarex and Bristol Myers Squibb Announces Enhanced Survival

Rate through Ipilimumab II-22

A Pain-Less Melanoma Test, Under Evaluation II-23

Encouraging Phase III Clinical Trials of a Melanoma Vaccine II-23

Plexxikon Announces Phase I Results of PLX4032" II-23

Provectus Treats Metastatic Melanoma Patients Under Phase II

Clinical Study with PV-10 II-24

GENOMEL Project Investigates Environmental/ Genetic Risk

Factors for Melanoma II-24

Antigenics Announces Results of a Phase III Trial of Oncophage

(vitespen) Vaccine II-25

CuraGen Advances Phase II Clinical Trial of "CR011-vcMMAE" II-25

Inovio Evaluates a Combination of Plasmid IL-12 and

Electroporation Technology for the Treatment of Metastatic

Melanoma II-25

6. RECENT INDUSTRY ACTIVITY II-27

Pfizer Collaborates with Debiopharm II-27

PharmaSynth Licenses Muparfostat to Global TransBiotech II-27

Celldex Therapeutics Acquires CuraGen II-27

Bristol-Myers Squibb Acquires Medarex II-28

Cephalon Acquires Outstanding Shares of Arana Therapeutics II-28

ImmunoVaccine Technologies Inks Agreement with Scancell II-29

Vical Inks Agreement with Abic for Allovectin-7 Immunotherapeutic II-29

Immunomedics Collaborates with Alexis Biotech II-29

NeoGenomics Signs Strategic Supply Deal with Abbott II-30

ErgoMed Collaborates with Genzyme II-30

PDS Biotechnology and Merck Eprova Sign CLA II-30

FDA Oncologic Drug Advisory Committee Recommends for Approval,

PEGINTRON® for Melanoma Treatment II-31

Takeda Acquires IDM Pharma II-31

Abraxis BioScience Receives FDA's Orphan Drug Status for Abraxane II-31

Progen Pharmaceuticals Spins-Off its Manufacturing Business II-32

Eli Lilly and Company Acquires SGX Pharmaceuticals II-32

GlaxoSmithKline and Synta Pharmaceutical Obtains the Orphan

Drug Status from the US FDA, for Elesclomol II-32

Vical Inks Binding LOI with EIP II-32

GammaCan Signs Supply Deal with Bio Products Laboratory II-33

Medarex and Bristol Myers Squibb Delays Submission of BLA, for

Ipilimumab II-33

Pfizer Discontinues Phase 3 Clinical Trials of Tremelimumab,

in Advanced Melanoma Patients II-34

Alnylam Pharmaceuticals Collaborates with University of

California to Evaluate an RNAi Therapeutic for Metastatic

Uveal Melanoma Treatment II-34

GenVec and Cobra Ink Manufacturing Agreement II-34

SciClone Pharmaceuticals Sings a Deal with FDA for Thymalfasin II-35

Abraxis BioScience, NCCN, and AstraZeneca Collaborates For

Assessment of Abraxane, the Anti-Cancer Drug II-35

Oxford BioMedica Acquires Oxxon Therapeutics II-36

7. FOCUS ON SELECT GLOBAL PLAYERS II-37

Abraxis BioScience, Inc. (USA) II-37

Astellas Pharma US, Inc. (USA) II-37

Antigenics Inc. (USA) II-37

AVAX Technologies, Inc. (USA) II-38

BioVex, Inc. (USA) II-38

GenVec, Inc. (USA) II-39

GlaxoSmithKline Plc. (UK) II-39

Medarex Inc. (USA) II-40

Merck KGAA (Germany) II-40

Oxford Biomedica Plc. (UK) II-40

Pfizer, Inc. (USA) II-41

Progen Pharmaceuticals Limited (Australia) II-41

Vical Inc. (USA) II-42

8. GLOBAL MARKET PERSPECTIVE II-43

Table 1: World Recent Past, Current & Future Analysis for

Melanoma Therapeutics Market by Geographic Region - US, and

Rest of World Markets Independently Analyzed by Annual Sales

Figures in US$ Million for the Years 2007 through 2015

(includes corresponding Graph/Chart) II-43

Table 2: World Historic Review for Melanoma Therapeutics

Market by Geographic Region - US, and Rest of World Markets

Independently Analyzed by Annual Sales Figures in US$ Million

for the Years 2001 through 2006 (includes corresponding

Graph/Chart) II-44

Table 3: World 15-Year Perspective for Melanoma Therapeutics

Market by Geographic Region - Percentage Breakdown of Sales

for the US, and Rest of World Markets for the Years 2003, 2009

& 2015 II-44

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Increasing Incidence of Melanoma Fuels Growth III-1

Table 4: Melanoma Incidence in the US by Gender: 2008 III-1

Table 5: Cancer Incidence in Males by Cancer Type:

Percentage Share Breakdown in 2008 (includes corresponding

Graph/Chart) III-1

Table 6: Cancer Incidence in Females by Cancer Type:

Percentage Share Breakdown in 2008 (includes corresponding

Graph/Chart) III-2

Surging Mortality, Demands Novel Therapeutics for Melanoma III-2

Table 7: Melanoma Mortality in the US by Gender: 2005 &

2008 (includes corresponding Graph/Chart) III-2

Table 8: Five-Year Survival Rate for Patients with Melanoma

of Skin in the US (1996-2003): Percentage Share Breakdown

by Diagnosis Stage (includes corresponding Graph/Chart) III-3

Fair-Skinned and Light Hair Whites at High Risk III-3

Table 9: Five-Year Survival Rate for Patients with Melanoma

of Skin in the US (1996-2003): Percentage Share Breakdown

by Race (includes corresponding Graph/Chart) III-3

US Melanoma Fact Sheet: A Recapitulation III-4

Major Players III-4

Strategic Corporate Developments III-8

B.Market Analytics III-15

Table 10: US Recent Past, Current & Future Analysis for

Melanoma Therapeutics Market with Annual Sales Figures in

US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-15

Table 11: US Historic Review for Melanoma Therapeutics

Market with Annual Sales Figures in US$ Million for Years

2001 through 2006 (includes corresponding Graph/Chart) III-15

2. REST OF WORLD III-16

A.Market Analysis III-16

Select Regional Markets Under Review III-16

Australia III-16

World's Leading Region with Highest Skin Cancer Incidence III-16

Table 12: Melanoma Incidence Rate in Australia by Age

Group: 2008 (2008) (includes corresponding Graph/Chart) III-16

Table 13: Melanoma Incidence Rate in Australian Males by

Age Group: 2008 (includes corresponding Graph/Chart) III-16

Table 14: Melanoma Incidence Rate in Australian Females

by Age Group: 2008 (includes corresponding Graph/Chart) III-17

Other Key Facts on Melanoma Incidence in Australia III-17

The United Kingdom III-17

Young Women in UK Becoming Increasing Victims of Melanoma III-17

Table 15: Newly Diagnosed Cases of Melanoma of Skin in

the UK (2003-2005): Breakdown by Select Regions, and

Gender (includes corresponding Graph/Chart) III-18

Table 16: Mortality Due to Melanoma of Skin in the UK

(2003-2005): Breakdown by Select Regions, and Gender

(includes corresponding Graph/Chart) III-18

Major Players III-18

Strategic Corporate Developments III-20

B.Market Analytics III-24

Table 17: Rest of World Recent Past, Current & Future

Analysis for Melanoma Therapeutics Market with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-24

Table 18: Rest of World Historic Analysis for Melanoma

Therapeutics Market with Annual Sales Figures in US$ Million

for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-24

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 73 (including Divisions/Subsidiaries - 80)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 59

Canada 2

Japan 1

Europe 13

France 1

Germany 5

The United Kingdom 4

Rest of Europe 3

Asia-Pacific (Excluding Japan) 3

Middle East 2

------------------------------------------

To order this report:

Drug and Medication Industry: Global Melanoma Therapeutics industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):